Breaking the Code for Better Health

Katrine Bosley, Editas Medicine

A timely examination of breakthroughs in genomic engineering to fight human diseases.

Katrine Bosley, Chief Executive, Editas Medicine

Katrine Bosley, CEO at Editas Medicine, was recently the entrepreneur-in-residence at the Broad Institute, a biomedical and genomic research center, and before that, the CEO of Avila Therapeutics (acquired by Celgene). She was vice president for business development at Adnexus Therapeutics and then vice president for strategic operations after Adnexus was acquired by Bristol-Myers Squibb. Earlier, Bosley held several positions at Biogen in business development, commercial operations, and portfolio strategy and was part of the health-care team at the venture firm Highland Capital Partners. She received a bachelor's degree from Cornell University. She board chairman for Genocea Biosciences and serves as a board member of Galapagos NV, Scholar Rock, and the Biotechnology Innovation Organization (BIO), as well as a review committee member for the Translation Fund of the Wellcome Trust.


What it means to be constantly connected with each other and vast sources of information.

Please enter your email address to view this free video.

We'd like to keep in touch about future MIT Technology Review initiatives and events.